Dyne Therapeutics, Inc. (DYN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Dyne Therapeutics reported revenue of $0. Net income was -$446.2M, or -$3.47 per diluted share. Operating activities generated -$403.2M of cash, leaving -$405.1M of free cash flow. At fiscal year end, Dyne Therapeutics held $1.19B in total assets against $214.8M in total liabilities, including $893.4M of cash and equivalents.
Open the full interactive Dyne Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Dyne Therapeutics Key Stats
| Share Price | $15.30 |
|---|---|
| 52-Week Range | $14.03 – $26.78 |
| Shares Outstanding | 51.7 million (basic, 2022 Q2) |
Dyne Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$58.6M | -$150.0M | -$171.0M | -$242.2M | -$343.9M | -$468.2M |
| Pre-Tax Income | -$59.4M | -$149.3M | -$168.1M | -$235.9M | -$317.4M | -$446.2M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$59.4M | -$149.3M | -$168.1M | -$235.9M | -$317.4M | -$446.2M |
| Diluted EPS | -$4.13 | -$2.93 | -$3.23 | -$3.95 | -$3.37 | -$3.47 |
Dyne Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$108.0M | -$112.0M | -$120.9M | -$178.6M |
| Diluted EPS | -$0.76 | — | -$0.73 | -$1.08 |
Dyne Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $300.9M | $200.8M | $172.1M | $121.6M | $435.4M | $893.4M |
| Current Assets | $349.1M | $382.4M | $265.6M | $129.4M | $659.3M | $1.13B |
| Total Assets | $353.3M | $425.7M | $306.3M | $165.1M | $691.2M | $1.19B |
| Current Liabilities | $11.0M | $28.7M | $28.1M | $51.1M | $42.3M | $50.6M |
| Total Long-Term Debt | — | — | — | — | — | $148.9M |
| Total Liabilities | $11.0M | $57.5M | $54.0M | $73.8M | $61.4M | $214.8M |
| Shareholders' Equity | $342.4M | $368.2M | $252.4M | $91.3M | $629.8M | $972.1M |
Dyne Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$46.5M | -$119.6M | -$153.6M | -$188.2M | -$292.4M | -$403.2M |
| Cash From Investing | -$45.7M | -$137.9M | $87.2M | $83.3M | -$204.1M | -$28.8M |
| Cash From Financing | $380.7M | $157.8M | $37.4M | $54.3M | $809.9M | $890.3M |
| Free Cash Flow | -$47.7M | -$123.2M | -$156.7M | -$188.9M | -$294.7M | -$405.1M |
Figures from Dyne Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Dyne Therapeutics financials page for every line item.
Dyne Therapeutics Company Profile
| Ticker | DYN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001818794 |
Frequently Asked Questions
What was Dyne Therapeutics' revenue in fiscal 2025?
Dyne Therapeutics (DYN) reported revenue of $0 for fiscal 2025.
What is Dyne Therapeutics' annual revenue history?
Dyne Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Dyne Therapeutics' net income in fiscal 2025?
Dyne Therapeutics reported net income of -$446.2M for fiscal 2025.
What was Dyne Therapeutics' earnings per share (EPS) in fiscal 2025?
Dyne Therapeutics' diluted EPS was -$3.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Dyne Therapeutics generate in fiscal 2025?
Dyne Therapeutics generated -$405.1M of free cash flow in fiscal 2025.
What was Dyne Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Dyne Therapeutics reported revenue of $0.
How much debt does Dyne Therapeutics have?
Dyne Therapeutics reported $148.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Dyne Therapeutics are outstanding?
Dyne Therapeutics reported a weighted average of 51.7 million basic shares outstanding in 2022 Q2.
When does Dyne Therapeutics' fiscal year end?
Dyne Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Dyne Therapeutics headquartered?
Dyne Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.